Recent developments in the first detection of hepatocellular carcinoma

Area of Science:

• Hepatology
• Oncology
• Biochemistry

Background:

• Hepatocellular carcinoma (HCC) is a globally prevalent cancer, primarily linked to Hepatitis B Virus (HBV) and increasingly Hepatitis C Virus (HCV).
• Alpha-fetoprotein (AFP) is the primary tumor marker for HCC, used alongside ultrasonography for screening high-risk individuals.
• Current screening intervals for HCC typically range from every 3 to 12 months, with 6-month intervals being most common.

Purpose of the Study:

• To review the efficacy of alpha-fetoprotein (AFP) as a tumor marker for hepatocellular carcinoma (HCC).
• To explore the utility of combining AFP with other biomarkers for enhanced HCC detection.
• To assess the potential of novel markers in improving HCC diagnosis and management.

Main Methods:

• Literature review of existing studies on HCC tumor markers.
• Analysis of the specificity and sensitivity of AFP and other biomarkers.
• Evaluation of emerging markers and proteomic signatures for HCC detection.

Main Results:

• AFP, while specific, demonstrates limited sensitivity for HCC detection.
• Combining AFP with markers like des-gamma-carboxy-prothrombin (DCP) and AFP fractions (L3, P4/5, +II) improves diagnostic sensitivity.
• Other markers like CA 125 show higher sensitivity but lower specificity than AFP; novel markers show promise but are not yet in routine use.

Conclusions:

• Enhanced screening for hepatocellular carcinoma (HCC) involves combining alpha-fetoprotein (AFP) with other validated tumor markers.
• Further research into novel biomarkers and proteomics is crucial for improving early HCC detection and patient outcomes.
• The development of more sensitive and specific markers is essential for effective HCC management.